January 17, 2023
1 minute read
Amylyx Pharmaceuticals Inc. has announced an exclusive licensing and distribution agreement with Neopharm for the commercialization of ALS treatment AMX0035 in Israel, Gaza, the West Bank and the Palestinian Authority.
“This agreement with Neofarm, if approved, is an important step towards expanding the availability of AMX0035 in the EMEA (Europe, Middle East and Africa) region.” Stephanie Hoffmannjandevien, Amylyx general manager and head of EMEA said in a company release. “Our team is steadfast in our mission to help every eligible person living with ALS have access to his AMX0035.”
The terms of the agreement, according to the release, are that Neopharm will receive exclusive rights to commercialize AMX0035 — an oral fixed dose of sodium phenylbutyrate and ursodoxycortaurine — in the above-mentioned Middle East region, along with all regulatory submissions and submissions. It stipulates that we are responsible for Obligations necessary for drug registration and reimbursement.
“We are honored to have AMX0035 added to our portfolio and to be given the opportunity to serve the ALS community both inside and outside Israel.” Effie schneidmann, The general manager of Neofarm Israel said in a release: We look forward to working with Amylyx to help her ALS patients who may benefit from this important new treatment option. “